DAX19.970 -1,4%ESt504.879 -1,6%Top 10 Crypto15,09 -7,4%Dow42.342 ±0,0%Nas19.373 -0,1%Bitcoin93.783 -0,6%Euro1,0365 ±-0,0%Öl72,67 -0,4%Gold2.594 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T NVIDIA 918422 Rheinmetall 703000 Amazon 906866 Palantir A2QA4J MicroStrategy 722713 Bayer BAY001 Micron Technology 869020 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y Atos 877757 Apple 865985 Commerzbank CBK100 Mercedes-Benz Group (ex Daimler) 710000 RWE 703712
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Fed-Leitzinssenkung: DAX schließt unter 20.000 -- US-Börsen kaum verändert -- Rheinmetall erhält Milliarden-Aufträge -- Adnoc erreicht bei Covestro Squeeze-out-Grenze -- Micron, Douglas im Fokus
Top News
Mit Satelliten-Kommunikation in die Zukunft: Apple setzt mit Apple Watch Ultra neue Maßstäbe Mit Satelliten-Kommunikation in die Zukunft: Apple setzt mit Apple Watch Ultra neue Maßstäbe
NVIDIA-Aktie & Co. in 2025: Analyst sieht besorgniserregendes Zeichen für Tech-Aktien NVIDIA-Aktie & Co. in 2025: Analyst sieht besorgniserregendes Zeichen für Tech-Aktien
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

BioNTech (ADRs) Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
108,00 EUR +1,00 EUR +0,93 %
FSE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.25,73 Mrd. EUR

KGV25,25Div. Rendite0,00%

WKNA2PSR2

ISINUS09075V1026

SymbolBNTX

BioNTech (ADRs) Aktien News

DatumMeistgelesen
PR NewswireROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
RSSBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 
GlobeNewswireBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
RSSBioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
GlobeNewswireBioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
EQS GroupEQS-News: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
EQS GroupEQS-News: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
PR NewswireSHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind BioNTech Investors of a Lead Plaintiff Deadline of March 12, 2024
EQS GroupEQS-News: ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
PR NewswireROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
EQS GroupEQS-News: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
RSSBioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
GlobeNewswireBioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
EQS GroupEQS-News: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
EQS GroupEQS-News: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
PR NewswireBNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BenzingaBioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025
BenzingaP/E Ratio Insights for BioNTech
Business TimesBioNTech predicts return to revenue growth in 2025
RSS6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
RSSBioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswireBioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
RSS144: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
BenzingaComparative Study: BioNTech And Industry Competitors In Biotechnology Industry
RSSBioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
GlobeNewswireBioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
RSSBioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswireBioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
RSSBioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
RSSBioNTech to Inaugurate First African Site on December 18, 2023
GlobeNewswireBioNTech to Inaugurate First African Site on December 18, 2023
RSSBioNTech and Australia’s State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem
RSSBioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswireBioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX
RSSBioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting

BioNTech (ADRs) News

BioNTech (ADRs) News: auf dieser Seite finden Sie alle BioNTech (ADRs) News und Nachrichten zur BioNTech (ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch BioNTech (ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um BioNTech (ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.